Drug Patents owned by Emd Serono Inc

1. List of Mavenclad drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785415 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(1 year, 2 months from now)

US7888328 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(1 year, 2 months from now)

US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
May, 2026

(3 years from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
Oct, 2026

(3 years from now)

US10849919 EMD SERONO INC Cladribine regimen for treating progressive forms of multiple sclerosis
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a solid oral form, w/o sign. amounts of cryst. 2cda; Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusion complex, cladribine/cyclodextrin 1:10-1:16 w/w; Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1.7 mg/kg cladribine; (iv) cladribine-free period; Treating ms with oral cladribine acc. to the steps (i) induction period with about 1.7 mg/kg-3.5 mg/kg cladribine; (iii) maintenance period with about 1.7 mg/kg cladribine; Treating non-early spms by administering oral cladribine at a fixed dose per patient, per body weight and per treatment year, which fixed dose is 1.75 +/- 0.2 mg/kg, to be administered within months 1 and 2 in each of 2 adjacent treatment years

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's patent expiration?
More Information on Dosage

MAVENCLAD family patents

17

United States

13

European Union

10

Japan

8

Australia

8

Spain

5

Brazil

5

China

5

Canada

5

Denmark

4

Korea, Republic of

4

Poland

4

Lithuania

4

Mexico

4

Slovenia

4

Hungary

4

Portugal

4

EA

3

Ukraine

3

Cyprus

3

South Africa

3

Argentina

3

Singapore

3

ME

3

Croatia

3

Norway

2

Austria

2

Hong Kong

2

Luxembourg

2

Yugoslavia

2

Israel

2

Iceland

1

RS

1

Germany

1

Russia

1

Taiwan, Province of China

2. List of Tepmetko drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8921357 EMD SERONO INC Pyridazinone derivatives
May, 2028

(5 years from now)

US8329692 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Oct, 2029

(6 years from now)

US8580781 EMD SERONO INC Pyridazinone derivatives
Mar, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284300 EMD SERONO INC Pyridazinone derivatives
Apr, 2028

(5 years from now)

US9403799 EMD SERONO INC Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Jul, 2028

(5 years from now)

US9062029 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(5 years from now)

US8658643 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(5 years from now)

US8927540 EMD SERONO INC Pyridazinone derivatives
Jul, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 3, 2026
Orphan Drug Exclusivity (ODE) Feb 3, 2028

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 03 February, 2021

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib; Treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib

Dosage: TABLET;ORAL

More Information on Dosage

TEPMETKO family patents

10

United States

5

European Union

3

Poland

3

Spain

3

Cyprus

3

Slovenia

3

Portugal

3

Croatia

3

Denmark

2

Hong Kong

2

Korea, Republic of

2

Brazil

2

Australia

2

Lithuania

2

Malaysia

2

Ukraine

2

Israel

2

Japan

2

Hungary

2

Argentina

2

Colombia

2

China

2

EA

2

Canada

2

New Zealand

2

Ecuador

1

Chile

1

Netherlands

1

Germany

1

South Africa

1

Peru

1

Singapore

1

Norway

1

Taiwan, Province of China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in